UK manufacturer JEB Technologies Ltd, a specialist product development company for the medical device industry will be joining the UK Pavilion at MEDICA 2022 to showcase a novel device that is designed to facilitate the taking of prostate biopsies.
The CamPROBE device (Cambridge Prostate Biopsy Device) aims to provide a
simple and low-cost alternative to the current methods for acquiring prostate tissue to subsequently diagnose the presence of prostate cancer. The device is intended to facilitate transperineal prostate biopsies under local anaesthetic.
The transrectal biopsy route (the current and most common method for prostate biopsies) can carry a significant risk of infections and severe sepsis as during the transrectal approach the needle has to traverse the bowel a number of times on the way to the prostate.
CamPROBE however, facilitates biopsies through the more sterile perineal skin (transperineal) under the genitals using simultaneous local anaesthetic delivery through an integrated needle system. It is an alternative to the transrectal approach and to other current transperineal devices and only needs two body entry puncture points, resulting in low pain scores, enhanced patient comfort and patient acceptability. Initial indications are that cancer detection ability is equivalent to other biopsy methods based on a multicenter clinical investigation. Access through the perineum virtually eliminates the risks of infection and sepsis Compared to transrectal procedures.
Sean Licence, Business Development at JEB Technologies said: “We are delighted to be joining the ABHI UK Pavilion again at MEDICA this year where we will be introducing a disruptive technology to facilitate the acquisition of prostate biopsies through the transperineal route. We have developed CamPROBE in the UK in conjunction with the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust.
“We are planning further clinical trials and post market activities that will aim to prove that CamPROBE is the optimum device for safe, simple, low-cost prostate biopsies that can be performed in an outpatient setting under local anaesthetic.
“Our aim is to make the lives of patients better through a simple and low painful approach of prostate cancer detection and this very common procedure will hopefully benefit the millions of men who have prostate biopsies every year. We look forward to meeting new partners at the event.”
The CamPROBE device (Cambridge Prostate Biopsy Device) is a surgically invasive, transient, single use, sterile device consisting of a stainless-steel cannula and an integrated coaxial needle , inserted at 2 points on either side of the perineal mid-line.
It is then advanced to the prostate with simultaneous targeted local anaesthetic infiltration to deeper structures (including pelvic muscles) using the integrated delivery needle and under transrectal ultrasound guidance.
Once in position, the delivery needle is removed and the CamPROBE cannula can be used as an access sheath for prostate biopsies. The CamPROBE can be angled or re-positioned to reach different areas without superficial or deep structure re-puncture.
With over 2 million biopsies occurring each year in Europe and North America 1  , We are very hopeful that CamPROBE will be adopted worldwide to facilitate prostate cancer detection.
MEDICA is taking place from 14 - 17 th November 2022 and throughout the show, JEB Technologies Ltd will be located on the ABHI UK Pavilion – Hall 16 stand H42.
For more information about JEB Technologies please visit https://jeb-
 Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, et al. Complications after
systematic, random, and image-guided prostate biopsy. Eur Urol. 2017;71:353–65.